Gilboa Therapeutics Presents Pre-clinical Data at AACR Supporting SolidT Engineered T-Cell Platform Targeting Solid Tumors webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.
Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the publication of a scientific paper demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed. The paper was published in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The company will be presenting its data in a poster at the AACR Annual Me.